Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats (Q51366978)
Jump to navigation
Jump to search
scientific article published on November 13, 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats |
scientific article published on November 13, 2011 |
Statements
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats (English)
1 reference
Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats (English)
1 reference
L. Thomas
R. Grempler
M. Eckhardt
F. Himmelsbach
A. Sauer
T. Klein
P. Eickelmann
13 November 2011
1 reference
1 reference
14
1 reference
1
1 reference
94-96
1 reference
1 reference
1 reference
1 reference
1 reference